Pharmaceuticals, Biotechnology and Life Sciences
The study provides a definition for Tumor Treating Fields dose and sets a framework for future work on Tumor Treating…
Total revenues of $498 million (+30% vs Q1 2018) and total product-related revenues of $458 million (+20% vs Q1 2018) for the…
Allotex has treated over 50 eyes in the first phase of its clinical trials.
DUBLIN–(BUSINESS WIRE)–The “Pharma Clinical Trial Digitization – Companies to Action, 2019” report has been added to ResearchAndMarkets.com’s offering. Despite the…
Revenue of $200.7 million in the first quarter of 2019 increased 23.1% from revenue of $163.1 million for the comparable…
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Beam Therapeutics, a biotechnology company developing precision genetic medicines through base editing, today announced the presentation of preclinical…
Eric Feldman, M.D.,a specialist in leukemia and bone marrow disorder therapies, has beenappointed Vice President of Clinical Development GlycoMimetics.
DUBLIN–(BUSINESS WIRE)–The “Global Erectile Dysfunction (ED) Drugs Market 2019-2023” report has been added to ResearchAndMarkets.com’s offering. The erectile dysfunction (ED)…
Pfizer has received positive opinion recommending TALZENNA (talazoparib), an oral poly (ADP-ribose) polymerase (PARP) inhibitor
ULTOMIRIS has the potential to become the new standard of care forboth complement inhibitor-naïve patients and patients switching fromSOLIRIS (eculizumab) –